Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2013. The report details a specific share repurchase transaction executed on July 4, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 410,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,688.50 pence per share; lowest price paid was 1,667 pence per share.
- Treasury Holdings (Settled): 501,014,512 shares, representing 9.26% of total issued share capital.
- Treasury Holdings (Including Unsettled): 502,849,512 shares, representing 10.24% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,909,366,589 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 410,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury to 10.24% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (501,014,512 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 4,909,366,589 shares (excluding Treasury).
- Check subsequent filings to determine if the 10.24% Treasury holding (including unsettled shares) was finalized as reported.